Astellas Pharma (4503.T) EBITDA

Price: $1404
Market Cap: $2.51T
Avg Volume: 6.32M
Country: JP
Industry: Drug Manufacturers - General
Sector: Healthcare
Beta: 0.157
52W Range: $1403-1835
Website: Astellas Pharma

What is Astellas Pharma's EBITDA?

  • Astellas Pharma's annual EBITDA is $195.34B.
  • Astellas Pharma's quarterly EBITDA is $126.06B.

What is EBITDA?

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.

How is EBITDA calculated?

EBITDA is calculated using the following formula:

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Related Metrics

Other important metrics to assess Astellas Pharma's financial health include:

  • EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
    • Annual: 12.18%
    • Quarterly: 24.36%
  • Growth EBITDA - measures the annual growth rate of the company's EBITDA:
    • Annual: -18.76%
    • Quarterly: 33.97%
  • Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
    • Annual: -25.01%
    • Quarterly: 19.76%

These metrics provide insights into Astellas Pharma's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual EBITDA

$195.34B

Quarterly EBITDA

$126.06B

Astellas Pharma Historical EBITDA
EBITDA (Annual)
EBITDA (Quarterly)
$360.00B$360.00B$270.00B$270.00B$180.00B$180.00B$90.00B$90.00B$0.00$0.00-$90.00B-$90.00BEBITDA201620162017201720182018201920192020202020212021202220222023202320242024
Historical EBITDA Ratio (Annual)
26.50%26.50%21.20%21.20%15.90%15.90%10.60%10.60%5.30%5.30%0.00%0.00%EBITDA Ratio201620162017201720182018201920192020202020212021202220222023202320242024
Historical EBITDA Ratio (Quarterly)
32.58%32.58%24.78%24.78%16.98%16.98%9.17%9.17%1.37%1.37%-6.43%-6.43%EBITDA Ratio20162016201720172018201820192019202020202021202120222022202320232024202420252025

Astellas Pharma Historical EBITDA Metrics

The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2023.

Year EBITDA Growth EBITDA EBITDA Ratio Growth EBITDA Ratio
2023 $195.34B -18.76% 12.18% -25.01%
2022 $240.46B -0.24% 16.24% -3.11%
2021 $241.03B 9.64% 16.76% -4.92%
2020 $219.83B -30.52% 17.63% -27.13%
2019 $316.41B 0.86% 24.20% 0.75%
2018 $313.73B 10.36% 24.02% 9.66%
2017 $284.28B -18.05% 21.90% -17.35%
2016 $346.90B 4.42% 26.50% 9.36%
2015 $332.21B 29.96% 24.23% 17.02%
2014 $255.62B 36.89% 20.70% 25.58%

Related Metrics

Explore detailed financial metrics and analysis for 4503.T.

Financial Analysis
Financial Statements Stock Forecast Price Target Technical Analysis Stock Splits Employee Count
Company Intelligence
Ownership Insider Trading SEC Filings Congress Trading News Earnings Call Transcripts
Income & Revenue
Earnings Revenue Revenue Growth Profit Net Income Profit Margin EBITDA Free Cash Flow Revenue Segments
Valuation
Valuation Market Cap Enterprise Value P/E Ratio PEG Ratio P/S Ratio P/B Ratio Book Value
Returns & Ratios
ROIC ROE ROA Current Ratio Quick Ratio Debt/Equity Ratio Earnings Per Share
Balance Sheet
Assets Debt Cash On Hand Shares Outstanding
Dividends
Dividends Dividend Yield Payout Ratio